Results from Cox regression models for CAD versus PAD
| HR unadjusted | P value | HR adjusted* | P value | |
| 3-point MACE | 1.78 (1.42 to 2.23) | <0.001 | 1.48 (1.15 to 1.91) | 0.002 |
| Vascular mortality | 1.71 (1.24 to 2.36) | 0.001 | 1.33 (0.93 to 1.92) | 0.119 |
| Stroke | 2.11 (1.42 to 3.13) | <0.001 | 1.66 (1.07 to 2.58) | 0.024 |
| MCI | 2.40 (1.68 to 3.41) | <0.001 | 1.98 (1.34 to 2.93) | 0.001 |
| All-cause mortality | 1.80 (1.48 to 2.20) | <0.001 | 1.32 (1.06 to 1.64) | 0.013 |
*Adjustments were made for age, gender, BMI, history of smoking, arterial hypertension, systolic blood pressure, LDL cholesterol, HDL cholesterol, HbA1c, eGFR, use of statins, ACE-inhibitors/ATII RBA and aspirin/clopidogrel.
ACE, angiotensin converting enzyme; ATII RBA, ATII receptor blocking agents; BMI, body mass index; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; MCI, myocardial infarction; PAD, peripheral artery disease; 3-point MACE, major cardiovascular endpoint (including cardiovascular death, non-fatal myocardial infarction and non-fatal stroke).